EAGAN, Minn.--(BUSINESS WIRE)--German regulatory authorities have granted approval to Biothera to conduct two open label, multicenter, randomized Phase II clinical trials studying Imprime PGG® administered in combination with monoclonal antibodies and chemotherapy in patients with non-small cell lung cancer (NSCLC), the company announced today.
